

What to Do When Patients Wish to Discontinue Their Psychotropic Medications? Effective Tapering Strategies to Limit Drug Withdrawal and Destabilization: a Clinician's Perspective

by Jonathan E. Prousky, ND, MSc

References

1. Moncrieff J. Why is it so difficult to stop psychiatric drug treatment? It may be nothing to do with the original problem. *Med Hypotheses*. 2006;67:517–523.
2. O'Brien CP. Benzodiazepine use, abuse, and dependence. *J Clin Psychiatry*. 2005;66 (Suppl 2):28–33.
3. Moncrieff J, Cohen D. Do antidepressants cure or create abnormal brain states? *PLoS Med*. 2006;3(7):e240.
4. Moncrieff J, Cohen D. How do psychiatric drugs work? *BMJ*. 2009;338:1535–1537.
5. Read J. *Coping with Coming Off: Mind's Research into the Experiences of People Trying to Come Off Psychiatric Drugs*. London: Mind Publications. 2005.
6. Howland RH. Potential adverse effects of discontinuing psychotropic drugs. Part 2: antidepressant drugs. *J Psychosoc Nurs Ment Health Serv*. 2010;48(7):9–12.
7. Howland RH. Potential adverse effects of discontinuing psychotropic drugs. Part 3: antipsychotic, dopaminergic, and mood-stabilizing drugs. *J Psychosoc Nurs Ment Health Serv*. 2010;48(8):11–14.
8. Lalive AL, Rudolph U, Lüscher C. Is there a way to curb benzodiazepine addiction? *Swiss Med Wkly*. 2011;141:w13277.
9. Darton K. *Making Sense of Coming Off Psychiatric Drugs*. London: Mind Publications; 2005.
10. Hall W. Harm reduction guide to coming off psychiatric drugs [online document]. Icarus Project and Freedom Center. September 2007. www.theicarusproject.net/downloads/ComingOffPsychDrugsHarmReductGuide1Edonline.pdf. Accessed November 5, 2012.



11. Baandrup L, Fagerlund B, Jennum P, et al. Prolonged-release melatonin versus placebo for benzodiazepine discontinuation in patients with schizophrenia: a randomized clinical trial – the SMART trial protocol. *BMC Psychiatry*. 2011;11:160.
12. Dagan Y, Zisapel N, Nof D, et al. Rapid reversal of tolerance to benzodiazepine hypnotics by treatment with oral melatonin: a case report. *Eur Neuropsychopharmacol*. 1997;7:157–160.
13. Peles E, Hetzroni T, Bar-Hamburger R, et al. Melatonin for perceived sleep disturbances associated with benzodiazepine withdrawal among patients in methadone maintenance treatment: a double-blind randomized clinical trial. *Addiction*. 2007;102:1947–1953.

Invigorate *Your* Mitochondria

ATP 360™ is a complete mitochondrial complex, clinically researched to provide targeted support for...

Mitochondrial Function

- Proprietary phospholipid blend promotes a healthy membrane*
- Antioxidants to support against oxidative stress*
- Healthy membrane is essential for vigorous ATP production*

Krebs Cycle

- Key nutrients to optimize Krebs energy production*

Mitogenesis & Membrane Potential

- Provides nutrients for optimizing the electron transport chain*
- PQQ to promote healthy mitochondrial mass*
- Promote healthy mitochondrial formation*

Visit www.ResearchedNutritionals.com/atp-360 for a full list of ingredients

Researched Nutritionals
Tel: 800.755.3402 • Fax: 805.693.1806 • CustomerService@ResearchedNutritionals.com
www.ResearchedNutritionals.com | Available only through healthcare professionals.

*These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.

14. Prousky J. Niacinamide's potent role in alleviating anxiety with its benzodiazepine-like properties: a case report. *J Orthomol Med*. 2004;19:104–110.
15. Horsman MR, Høyer M, Honess DJ. Nicotinamide pharmacokinetics in humans and mice: a comparative assessment and the implications for radiotherapy. *Radiother Oncol*. 1993;27:131–139.
16. Pasco Neurapas® CTD Documentation. Module 2:2.7 Clinical Summary Neurapas® balance, film-coated tablets. 2005;1–165.
17. Werneke U, Turner T, Priebe S. Complementary medicines in psychiatry. *Br J Psychiatry*. 2006;188:109–121.
18. Pasco Neurapas® CTD Documentation. Module 2:2.5 Clinical Overview Neurapas® balance, film coated tablets. 2005;1–39.

19. Darbinyan V, Aslanyan G, Amroyan E, et al. Clinical trial of Rhodiola rosea L. extract SHR-5 in the treatment of mild to moderate depression. *Nord J Psychiatry*. 2007;61:343–348.
20. Bystritsky A, Kerwin L, Feusner JD. A pilot study of Rhodiola rosea (Rhodax) for generalized anxiety disorder (GAD). *J Altern Complement Med*. 2008;14:175–180.
21. Olsson EM, von Schéele B, Panossian AG. A randomised, double-blind, placebo-controlled, parallel-group study of the standardised extract shr-5 of the roots of Rhodiola rosea in the treatment of subjects with stress-related fatigue. *Planta Med*. 2009;75:105–112.
22. Rhodiola rosea [monograph]. *Altern Med Rev*. 2002;7:421–423.

23. Zhong-Hong L, Shen-yin Z, Guan-hua D. Comparison of the pharmacokinetics of salidroside and salidroside in the extracts of *Rhodiola rosea* L in rats. *Asian J Pharmacodynamin Pharmacokin*. 2006;6:224–226.

24. McGovern E, McDonnell TJ. Herbal medicine – sets the heart racing! *Ir Med J*. 2010;103:219.

25. Bronson PJ. A biochemist's experience with GABA. *J Orthomol Med*. 2011;26:11–14.

26. Gamma-aminobutyric acid (GABA) [monograph]. *Altern Med Rev*. 2007;12:274–279.

27. Braverman ER, Pfeiffer CC, Blum K, et al. *The Healing Nutrients Within*. 2nd ed. New Canaan, CT: Keats Publishing; 1997:246–47,247–58,290–303.

28. L-theanine [monograph]. *Altern Med Rev*. 2005;10:136–138.

29. Ritsner MS, Miodownik C, Ratner Y, et al. L-theanine relieves positive, activation, and anxiety symptoms in patients with schizophrenia and schizoaffective disorder: an 8-week, randomized, double-blind, placebo-controlled, 2-center study. *J Clin Psychiatry*. 2011;72:34–42.

30. Miodownik C, Maayan R, Ratner Y, et al. Serum levels of brain-derived neurotrophic factor and cortisol to sulfate of dehydroepiandrosterone molar ratio associated with clinical response to L-theanine as augmentation of antipsychotic therapy in schizophrenia and schizoaffective disorder patients. *Clin Neuropharmacol*. 2011;34:155–160.



**BOTANICAL-BASED
BLOOD SUGAR
SUPPORT***

Berberine 500
Metabolic Balance*

Supports healthy cholesterol and blood sugar within normal levels, and a normal balance of microbes in the respiratory and GI tracts.*

500 mg of pure, highly concentrated berberine HCl (97%) per vegetarian capsule from non-GMO Indian barberry, containing no common allergens.

Glucofit™
Standardized Corosolic Acid

Water extraction from *Lagerstroemia speciosa* L., standardized to 18% corosolic acid, that supports maintenance of a normal glycemic profile after meals.*

As a blood sugar regulating factor, may help support weight within normal levels.*

Glucose Tolerance II™
with Glucevia™ Complex

Contains Glucevia™ (European Ash extract) which may help reduce post-prandial glucose levels, support insulin sensitivity, and liver metabolism.*

Blood sugar support enhanced with berberine HCl, chromium, milk thistle, resveratrol, and biotin.*

*Glucose™ is a trademark of Glaxo.

*This statement has not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.



Call or order online today.
www.allergyresearchgroup.com
800.545.9960

Return to TownsendLetter.com